EU ‘negotiating with Valneva’ over COVID-19 vaccine contractThe European Commission is reportedly in advanced discussions with French biotech Valneva about picking up the contract to Share XEU ‘negotiating with Valneva’ over COVID-19 vaccine contracthttps://pharmaphorum.com/news/eu-negotiating-with-valneva-over-covid-19-vaccine-contract/
Valneva slumps as UK dumps €1.4bn order for COVID-19 jabThe UK has terminated its order for up to 190 million doses of a COVID-19 vaccine developed by Share XValneva slumps as UK dumps €1.4bn order for COVID-19 jabhttps://pharmaphorum.com/news/valneva-slumps-as-uk-dumps-e1-4bn-order-for-covid-19-jab/
NHS fast tracks access to Amgen’s just-approved KRAS cancer drugAmgen’s first-in-class KRAS inhibitor Lumykras has been approved in Great Britain and arrives already armed with an agreement Share XNHS fast tracks access to Amgen’s just-approved KRAS cancer drughttps://pharmaphorum.com/news/nhs-fast-tracks-access-to-amgens-just-approved-kras-cancer-drug/
MHRA clears third doses of AZ, Pfizer COVID jabsThe UK medicines regulator has cleared the use of a third dose of both the AstraZeneca and Pfizer Share XMHRA clears third doses of AZ, Pfizer COVID jabshttps://pharmaphorum.com/news/mhra-clears-third-doses-of-az-pfizer-covid-jabs/
Pfizer gets first approval, in UK, for Xeljanz follow-up CibinqoPfizer has claimed its first regulatory approval worldwide for Cibinqo, its JAK inhibitor for atopic dermatitis, from the Share XPfizer gets first approval, in UK, for Xeljanz follow-up Cibinqohttps://pharmaphorum.com/news/pfizer-gets-first-approval-in-uk-for-xeljanz-follow-up-cibinqo/
MHRA cuts could affect UK regulatory decisions, say unionsA 20% to 25% reduction in staffing at the UK Medicines and Healthcare products Regulatory Agency (MHRA) risks Share XMHRA cuts could affect UK regulatory decisions, say unionshttps://pharmaphorum.com/news/mhra-cuts-could-affect-uk-regulatory-decisions-say-unions/
MHRA clears Moderna COVID vaccine for 12 to 17 year oldsThe Moderna COVID-19 vaccine has become the second jab to be authorised for use in England, Scotland and Share XMHRA clears Moderna COVID vaccine for 12 to 17 year oldshttps://pharmaphorum.com/news/mhra-clears-moderna-covid-vaccine-for-12-to-17-year-olds/
Merck’s targeted lung cancer drug tepotinib wins early access in UKThe UK drugs regulator has backed Merck KGaA’s MET inhibitor for the treatment of some patients with non-small Share XMerck’s targeted lung cancer drug tepotinib wins early access in UKhttps://pharmaphorum.com/news/mercks-targeted-lung-cancer-drug-tepotinib-wins-early-access-in-uk/
MHRA grants bluebird ‘innovation passport’ for sickle cell therapybluebird bio’s sickle cell disease (CD) gene therapy LentiGlobin is the latest recipient of an ‘innovation passport’ introduced Share XMHRA grants bluebird ‘innovation passport’ for sickle cell therapyhttps://pharmaphorum.com/news/mhra-grants-bluebird-innovation-passport-for-sickle-cell-therapy/
